Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 18/20 | 0.70 |
| ▸ | ICAM1 | P05362 | 18/20 | 0.70 |
| ▸ | ITGAL | P20701 | 18/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18867795 | 0.91 | ITGB2 (0.69) | ITGB2ICAM1ITGALHDAC6CYP2C9 | |
| SCHEMBL18868483 | 0.89 | ITGB2 (0.74) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13665300 | 0.88 | ITGB2 (0.75) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18868611 | 0.88 | ITGB2 (0.65) | ITGB2ICAM1ITGALHDAC6CYP2C9 | |
| SCHEMBL13894109 | 0.87 | ITGB2 (0.57) | ITGB2ICAM1ITGAL | |
| SCHEMBL17991448 | 0.85 | ITGB2 (0.74) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13894108 | 0.84 | ITGB2 (0.65) | ITGB2ICAM1ITGALALDH1A1HDAC6 | |
| SCHEMBL18868521 | 0.84 | ITGB2 (0.75) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL16852208 | 0.84 | ITGB2 (0.75) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4756060 | 0.84 | ITGB2 (0.75) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3797775-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| EP-3167886-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | SARcode Bioscience Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2209371-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2009054914-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |